Hearts & Minds Blog

The History of LDL-Cholesterol with Dr. Antonio Gotto | Beyond Statins: The Evolution of Cholesterol Lowering Treatments

Tim Mayleben

President and Chief Executive Officer

Antonio M. Gotto, Jr., MD, DPhil

Dean Emeritus, Weill Cornell Medicine, and Provost for Medical Affairs Emeritus, Cornell University

In Part I of our “History of LDL-cholesterol” blog series, I sat down with cardiovascular and lipids specialist, Dr. Antonio M. Gotto, Jr,. to explore the discovery of cholesterol and the development of statins. To continue our conversation focused on cholesterol-lowering treatment options, our next session was centered around therapies that have emerged after statins, and how they have changed the cholesterol treatment landscape. Dr. Gotto’s expertise and years of clinical practice always make for an informative and insightful discussion. Read on for highlights from… more

The Bempedoic Acid / Ezetimibe Combo Pill: Our Leading Complementary, Non-statin, Oral Therapy

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

This week we announced a major milestone: the U.S. Food and Drug Administration (FDA) confirmed the regulatory pathway to approval for an LDL-cholesterol lowering indication for our once-daily, oral combination of bempedoic acid 180 mg and ezetimibe 10 mg. The complementary, non-statin combo pill lowers LDL–cholesterol (LDL-C) by almost 50%, while significantly reducing a key marker of inflammation associated with cardiovascular disease known as high-sensitivity C-reactive protein (hsCRP), while potentially lowering the occurrence of muscle-related side effects. As you may recall, this follows our March… more

Setting the Record Straight: The Facts About Bempedoic Acid

Tim Mayleben

President and Chief Executive Officer

We recently became aware of comments published containing misinterpretations or intentionally inaccurate statements regarding Esperion and bempedoic acid.  As the press release we issued referenced, we generally do not comment on these types of communications.  However, as lipid management experts we are compelled to set the record straight about Esperion, bempedoic acid, and our fixed-dose-combination. Bempedoic Acid Clinical Development and Need for Additional Treatment Options We have conducted the most robust clinical development program for an LDL-C lowering therapy in recent memory; over 1,000 patients… more

Cardiovascular Disease Awareness: Heart Healthy Initiatives Underway at Esperion

Tricia Mullins

Executive Director, Advocacy & Professional Relations

I am very excited to join my Esperion colleagues, their families and pets to participate in the Washtenaw County American Heart Association (AHA) Heart Walk on Saturday, May 6, 2017!  Our Esperion team will be joining nearly 1 million people at 305 events across the country to build healthier lives, free of cardiovascular diseases and stroke. At Esperion we are committed to promoting awareness for healthier lives and hearts.  Esperion has challenged our team of Lipid Management Experts to the FitBit Challenge, as we explore… more

ACC Scientific Session Reflections: A Conversation Among Members of The Lipid Management Team

Tim Mayleben

President and Chief Executive Officer

Mary McGowan

Chief Medical Officer

Marianne Andreach

Senior Vice President, Strategic Marketing and Product Planning

Last week The Lipid Management team attended the American College of Cardiology (ACC) 66th Annual Scientific Session in Washington D.C. where Dr. Brian A. Ference presented “Genetic Target Validation for ATP-Citrate Lyase Inhibition”, consisting of results from the Mendelian randomization studies conducted on the enzyme target of bempedoic acid, helping to further validate our therapeutic approach. Coupled with the highly-anticipated confirmation from the U.S. Food and Drug Administration (FDA) that our global pivotal Phase 3 program design can support approval for an LDL-C lowering indication,… more